GlassScriptPhysician profile
Philip T Thwing
NPI 1912093311
$3,569.40
in general payments reported to CMS, 2019-2025
29 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $282 · 2021: $494 · 2022: $809 · 2023: $214 · 2024: $296 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.08 | 2019-2024 | Jardiance |
| Abbvie INC. | $546.75 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $424.98 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $357.76 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $221.10 | 2021-2025 | Wegovy, Ozempic |
| Amgen INC. | $182.00 | 2019-2023 | Prolia, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.57 | 2024-2025 | Caplyta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $128.79 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $127.73 | 2021-2024 | |
| Welch Allyn | $99.98 | 2020 | |
| Mdd US Operations, LLC | $85.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $79.40 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $77.98 | 2021-2023 | Nexletol |
| Ucb, INC. | $75.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.58 | 2021 | |
| Dexcom, INC. | $31.29 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $26.07 | 2020-2021 | |
| Axsome Therapeutics, INC. | $23.75 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $22.03 | 2023 | Horizant |
| Philips North America LLC | $19.42 | 2024 | (Ck7) Extended Holter |
| Ultragenyx Pharmaceutical INC. | $19.13 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.84 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.92 | 2021 | |
| Insulet Corporation | $13.41 | 2024 | Omnipod |
| Allergan, INC. | $13.15 | 2020 | |
| Mylan Specialty L.P. | $12.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.63 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Thwing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.